Furman Smith
Optometrist · Mt Pleasant, SCNPI 1336129683
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,800 of the $21,272 with a category attached, or 60.2%. 24 manufacturers reported payments, led by Lumenis BE Inc at 32.4% of the total. Reporting peaked in 2024 at $5,320 and has fallen 75.2% since, to $1,317 in 2025. Among optometrist clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 194 payments — averaging $109.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lumenis BE Inc$7K
- Glaukos Corporation$2K
- Lumenis, Inc$2K
- Coopervision Inc.$2K
- Alcon$2K
- Johnson & Johnson Vision Care, Inc.$1K
- plus $5K from 18 others
What the payments were for
- Consulting fees$2,0009%
- Speaking & faculty fees$4,13419%
- Travel & lodging$1,8259%
- Food & beverage$12,80060%
- Education$1961%
- Entertainment$3171%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lumenis BE Inc | 3 | $6,901 |
| Glaukos Corporation | 4 | $2,253 |
| Lumenis, Inc | 2 | $2,154 |
| Coopervision Inc. | 20 | $1,970 |
| Alcon | 55 | $1,934 |
| Johnson & Johnson Vision Care, Inc. | 27 | $1,093 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $695 |
| Bausch & Lomb Americas Inc. | 14 | $688 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $606 |
| Amgen(2 entities) | 5 | $591 |
| AbbVie(2 entities) | 9 | $338 |
| Mallinckrodt Hospital Products Inc. | 5 | $336 |
| Oyster Point Pharma, Inc. | 9 | $320 |
| Optos, Inc. | 3 | $317 |
| Sun Pharmaceutical Industries Inc. | 7 | $285 |
| Shire North American Group Inc | 2 | $174 |
| Astellas Pharma US Inc | 1 | $167 |
| Tarsus Pharmaceuticals, Inc. | 6 | $143 |
| Carl Zeiss Meditec, Inc. | 1 | $90 |
| Novartis | 4 | $74 |
| Biotissue Holdings Inc. | 2 | $73 |
| Alcon Research LLC | 1 | $31 |
| Dompe US, Inc. | 1 | $22 |
| Tearlab Corp | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- M22$4,101
- optilight$2,800
- Lumenis Pulse 120H$2,134
- MiSight Contact Lens$1,177
- TEPEZZA$591
- TearScience Lipiflow System$588
- TearScience Lipiview System$588
- TearScience Lipiscan System$588
- Precision7$264
- DAILIES$246
- PANORAMIC OPHTHALMOSCOPE$241
- OCT OPHTHALMOSCOPE$241
- XIIDRA$240
- Acuvue$225
- MyDay Contact Lens$203
- Izervay$167
- TOTAL30$148
- CE-marked KXLA system$137
- ULTRA$123
- NFC-700$120
How this compares
$21,272 in reported general payments places this provider in the 95th percentile of 653 optometrist providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MieboPerfluorohexyloctane/Pf | 21 | $36,574 |
| XiidraLifitegrast | 18 | $26,909 |
| TyrvayaVarenicline Tartrate | 22 | $26,198 |
| RestasisCyclosporine | 14 | $17,851 |
| LumiganBimatoprost | 17 | $11,191 |
| Cyclosporine | 20 | $9,005 |
| CombiganBrimonidine Tartrate/Timolol | 25 | $8,428 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 13 | $2,518 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 39 | $1,259 |
| Latanoprost | 77 | $985 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 12 | $690 |
| Brimonidine Tartrate | 17 | $669 |
| ErythromycinErythromycin Base | 16 | $170 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Miebo, Xiidra | $688 | $63,48339 claims |
| AbbVieRestasis, Lumigan, Combigan | $338 | $37,46956 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $320 | $26,19822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 653 optometrist providers in South Carolina.
Other optometrist in Mt Pleasant
- Elizabeth BraunMt Pleasant$8K
- Paul SalvatoreMt Pleasant$6K
- Thomas WeshefskyMyrtle Beach$77K
- Richard BedellCharleston$55K
- Patrick VollmerColumbia$49K
- William ColemanEasley$22K
- Jennifer ZolmanCharleston$21K
- Steven AndreasenGreenville$19K
- Bridget WhaleyGreenville$18K
- Scott OliverRock Hill$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.